Loading...
XTSESVA
Market cap49mUSD
Dec 24, Last price  
0.22CAD
1D
0.00%
1Q
-10.20%
Jan 2017
-26.67%
Name

Sernova Corp

Chart & Performance

D1W1MN
XTSE:SVA chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
13.72%
Rev. gr., 5y
%
Revenues
0k
88,0085,2840080,304000000000000000
Net income
-39m
L+58.92%
-368,374-433,564-1,257,169-3,592,220-2,753,485-1,468,361-1,846,371-2,016,744-2,568,028-2,002,921-2,746,059-2,859,477-2,499,622-2,639,479-3,698,627-3,978,540-5,407,586-7,023,907-24,538,538-38,997,520
CFO
-30m
L+110.38%
-648,092-239,101-758,631-2,225,322-1,249,178-574,196-825,729-901,179-1,569,040-1,205,046-1,704,561-2,164,790-2,553,055-2,740,359-3,916,011-4,192,390-3,939,199-6,843,744-14,421,398-30,339,117
Earnings
Jan 27, 2025

Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
IPO date
Apr 15, 1999
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑102022‑102021‑102020‑102019‑102018‑102017‑102016‑102015‑10
Income
Revenues
Cost of revenue
41,162
25,163
Unusual Expense (Income)
NOPBT
(41,162)
(25,163)
NOPBT Margin
Operating Taxes
(629)
118
Tax Rate
NOPAT
(40,533)
(25,281)
Net income
(38,998)
58.92%
(24,539)
249.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
20,279
BB yield
-9.27%
Debt
Debt current
136
140
Long-term debt
136
412
Deferred revenue
Other long-term liabilities
Net debt
(19,534)
(49,224)
Cash flow
Cash from operating activities
(30,339)
(14,421)
CAPEX
(99)
(329)
Cash from investing activities
34,781
(46,341)
Cash from financing activities
503
36,665
FCF
(40,387)
(25,758)
Balance
Cash
19,806
49,776
Long term investments
Excess cash
19,806
49,776
Stockholders' equity
(7,179)
35,115
Invested Capital
19,830
12,770
ROIC
ROCE
EV
Common stock shares outstanding
303,332
273,593
Price
0.76
-5.00%
0.80
-36.00%
Market cap
230,532
5.33%
218,875
-28.68%
EV
210,999
169,650
EBITDA
(40,716)
(24,723)
EV/EBITDA
Interest
32
118
Interest/NOPBT